Cargando…
Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label
Autores principales: | Dal-Ré, Rafael, Launay, Odile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190873/ https://www.ncbi.nlm.nih.gov/pubmed/34120766 http://dx.doi.org/10.1016/j.vaccine.2021.05.095 |
Ejemplares similares
-
The impact of the AstraZeneca suspensions on the public’s vaccination intentions and trust: Marion de Vries
por: de Vries, M, et al.
Publicado: (2022) -
When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine
por: Dal-Ré, Rafael, et al.
Publicado: (2021) -
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
por: Dal-Ré, Rafael
Publicado: (2023) -
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021) -
Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)